Belite Bio, a clinical-stage company developing treatments for degenerative retinal diseases, announced it will participate in a virtual investor symposium hosted by Piper Sandler on July 9, 2026. The company will engage in a fireside chat to discuss its lead drug candidate, tinlarebant, which targets Stargardt disease type 1 and geographic atrophy in dry age-related macular degeneration. Belite Bio recently completed a successful Phase 3 trial and is continuing further clinical studies. The webcast will be available on Belite Bio's investor relations website and archived for 90 days.
Bitget has expanded its API to include CFD trading for gold, foreign exchange, and stock indices, adding 16 new endpoints for market data, trading, position management, and account operations. This update allows programmatic traders to access traditi...
Imperial Petroleum reported record revenues and strong cash flow in the second quarter, alongside significant share repurchases. The company is benefiting from limited inventory availability controlled by the Vafias family, reducing the risk of share...
Coinbase has expanded its DeFi Earn product to Brazil by integrating with Morpho, an onchain lending protocol on the Base network. This new option allows Brazilian users to earn yields on their USDC holdings through decentralized finance. The move br...
Zcash (ZEC) experienced a sharp 14% price decline on September 11, 2026, falling to around $1,069 without any confirmed news or regulatory actions to explain the drop. Analysts point to a technical sell signal flagged the day before, indicating overb...
Bitcoin's price increased about 25%, from $63,000 to $79,000, while mid-sized coin inflows to major exchanges fell by 15.5%, indicating holders are reluctant to sell. This price rise was driven mainly by retail and institutional investors, with whale...
